RT Journal Article
T1 Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
A1 Rosen, Raymond C
A1 Wu, Frederick
A1 Behre, Hermann M
A1 Porst, Hartmut
A1 Meuleman, Eric J H
A1 Maggi, Mario
A1 Romero-Otero, Javier
A1 Martinez-Salamanca, Juan I
A1 Jones, Thomas Hugh
A1 Debruyne, Frans M J
A1 Kurth, Karl-Heinz
A1 Hackett, Geoff I
A1 Quinton, Richard
A1 Stroberg, Peter
A1 Reisman, Yacov
A1 Pescatori, Edoardo S
A1 Morales, Antonio
A1 Bassas, Lluis
A1 Cruz, Natalio
A1 Cunningham, Glenn R
A1 Wheaton, Olivia A
A1 RHYME Investigators, 
K1 Hypogonadism
K1 Phosphodiesterase Type 5 Inhibitors
K1 Quality of Life
K1 Sexual Function
K1 Testosterone Replacement Therapy
AB The benefits and risks of long-term testosterone administration have been a topic of much scientific and regulatory interest in recent years. To assess long-term quality of life (QOL) and sexual function benefits of testosterone replacement therapy (TRT) prospectively in a diverse, multinational cohort of men with hypogonadism. A multinational patient registry was used to assess long-term changes associated with TRT in middle-age and older men with hypogonadism. Comprehensive evaluations were conducted at 6, 12, 24, and 36 months after enrollment into the registry. QOL and sexual function were evaluated by validated measures, including the Aging Males' Symptom (AMS) Scale and the International Index of Erectile Function (IIEF). A total of 999 previously untreated men with hypogonadism were enrolled at 25 European centers, 750 of whom received TRT at at least one visit during the period of observation. Patients on TRT reported rapid and sustained improvements in QOL, with fewer sexual, psychological, and somatic symptoms. Modest improvements in QOL and sexual function, including erectile function, also were noted in RHYME patients not on TRT, although treated patients showed consistently greater benefit over time in all symptom domains compared with untreated patients. AMS total scores for patients on TRT were 32.8 (95% confidence interval = 31.3-34.4) compared with 36.6 (95% confidence interval = 34.8-38.5) for untreated patients (P  TRT-related benefits in QOL and sexual function are well maintained for up to 36 months after initiation of treatment. The major strengths are the large, diverse patient population being treated in multidisciplinary clinical settings. The major limitation is the frequency of switching from one formulation to another. Overall, we confirmed the broad and sustained benefits of TRT across major QOL dimensions, including sexual, somatic, and psychological health, which were sustained over 36 months in our treatment cohort. Rosen RC, Wu F, Behre H, et al. Quality of Life and Sexual Function Benefits Effects of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME). J Sex Med 2017;14:1104-1115.
YR 2017
FD 2017-08-07
LK http://hdl.handle.net/10668/11479
UL http://hdl.handle.net/10668/11479
LA en
DS RISalud
RD Apr 6, 2025